Organization
Chelsea Therapeutics
3 clinical trials
1 abstract
Clinical trial
A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensionStatus: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With FibromyalgiaStatus: Completed, Estimated PCD: 2011-10-01
Clinical trial
A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of CarbidopaStatus: Completed, Estimated PCD: 2011-05-01
Abstract
ABR-224050 A NOVEL DIHYDROOROTATE DEHYDROGENASE INHIBITOR SUPPRESSING DISEASE DEVELOPMENT IN COLLAGEN INDUCED ARTHRITIS IN DBA/1 MICEOrg: Research and Development Laboratories, Active Biotech Research AB, Lund, Sweden, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Chelsea Therapeutics,